Professional Documents
Culture Documents
2008;99:598-607
PRACTICAL DERMATOLOGY
Abstract. The term livedo reticularis refers to a reddish-violet reticular discoloration of the skin that mainly
affects the limbs. It is caused by an interruption of blood flow in the dermal arteries, either due to spasm,
inflammation, or vascular obstruction, and is associated with diseases of varying etiology and severity. To
establish the cause of livedo reticularis, it is essential to determine its course (chronic, acute, or fulminant),
the presence of other cutaneous signs such as nodules, retiform purpura or necrosis, and the possible
association of general symptoms or laboratory findings that suggest a particular systemic process. The aim of
this review is to describe the diagnosis and treatment of the disease.
Key words: livedo reticularis, retiform purpura, livedo racemosa, vasculitis, cholesterol emboli, calciphylax-
is, antiphospholipid antibodies.
The term livedo reticularis is used to describe a reticular To understand the events associated with livedo reticularis,
red-violaceous discoloration of the skin that typically affects it is necessary to be familiar with the anatomy and physiology
the limbs, although it can also be generalized. It is secondary of the cutaneous blood vessels. The skin, like any organ,
to organic or functional disorders of the dermal arteries or receives its blood supply via the arteries, which branch into
arterioles. Because arterioles can be affected by numerous arterioles at the junction between the dermis and the
conditions, livedo reticularis has many possible causes (Table subcutaneous cellular tissue to form the deep vascular plexus,
1). The condition has its origins in the reduction or which runs parallel to the epidermis. This plexus is formed
interruption of blood flow at certain points in the path of by the feeding artery and a network of arterioles measuring
the blood vessels due to spasm, inflammation of the arteriolar 100 µm in diameter; the walls of these vessels consist of
wall, or vascular obstruction. Vascular obstruction can, in 2 outer layers of muscle, an elastic lamina, and internally,
turn, be caused by thrombosis, embolic events, or vessel the vascular endothelium. Smaller, communicating arterioles
wall abnormalities. arise from the deep plexus and run perpendicularly to the
epidermis to reach the upper dermis, where they form the
superficial vascular plexus, which also runs parallel to the
Correspondence: epidermis. The arterioles here are very small (diameter,
Carmen Herrero Mateu
Servicio de Dermatología, Hospital Clínic
10 µm); their walls only have a single muscle layer and the
C/ Villarroel, 170, 08036 Barcelona, Spain internal elastic lamina is absent. The superficial plexus gives
cherrero@clinic.ub.es
rise to capillaries that supply blood to the papillae; the blood
Manuscript accepted for publication February 2, 2008. then drains through the postcapillary venules into larger
598
Herrero C et al. Diagnosis and Treatment of Livedo Reticularis on the Legs
Table 1. Causes of Livedo Reticularis Table 2. Clinical Associations of Livedo Reticularis With
Purpura, Necrosis, and/or Nodules
Arteriolar spasm Response to cold
Isolated Livedo Livedo Reticularis with Retiform
Drug-induced Reticularis (Caused Purpura, Necrosis, Ulcers, Nodules
(ergotamine, cocaine) by Spasm) (Caused by Vascular Obstruction)
Vessel Inflammation Cold
Noninfectious (vasculitis) Systemic polyarteritis nodosa Drugs
Cutaneous polyarteritis nodosa
Wegener granulomatosis SLE, RA
Churg–Strauss syndrome Polyarteritis Nodosa Polyarteritis Nodosa
Microscopic polyangiitis Wegener granulomatosis,
Drug-induced vasculitis (thiouracil) Churg–Strauss syndrome,
Vasculitis associated with microscopy polyangiitis, SLE, RA
SLE or RA Drug-induced vasculitis (thiouracil)
Lucio’s phenomenon
Infectious Lucio’s phenomenon
Sneddon syndrome
Vascular Obstruction Without Inflammation
Antiphospholipid Antiphospholipid syndrome
Thrombosis Antiphospholipid syndrome syndrome Livedoid vasculopathy
Sneddon syndrome Disseminated intravascular
Livedoid vasculopathy coagulation
SLE, RA Coumarin-induced necrosis
Coumarin-induced necrosis Type I cryoglobulinemia
Disseminated intravascular Thrombophilia
Sickle cell anemia
coagulation
Drugs
Dysproteinemia Atrial myxoma
(type I cryoglobulinemia) Cholesterol
Procoagulant genetic factors Calciphylaxis
(factor V) Primary hyperoxaluria
Sickle cell anemia
Drugs Abbreviations: RA, rheumatoid arthritis; SLE, systemic lupus
erythematosus.
Embolization Atrial myxoma
Cholesterol
Figure 1. Schematic
Livedo reticularis Livedo racemosa Retiform purpura representation of livedo
reticularis, livedo racemosa
(functional) (organic)
and retiform purpura. Adapted
from Sepp.35
Laboratory tests should include a complete blood count, as the reponse to cold in an attempt to maintain body
coagulation studies, evaluation of kidney function, urinary temperature, or may be a response to certain drugs. It is
sediment, proteinuria, antinuclear antibodies, complement well known that ergotamine and other alkaloids derived
levels, antineutrophil cytoplasmic antibodies (ANCAs), from rye ergot—once used to induce postpartum uterine
cryoglobulin and cryofibrinogen levels, antiphospholipid contraction—can cause vasoconstriction. The constrictor
antibodies, and hepatitis B and C serology. It is sometimes response in such cases is so strong that it can cause severe
necessary to conduct a more comprehensive study of necrosis in the limbs. Other drugs known to cause
coagulation factors such as protein C and S levels, factor vasoconstriction are cocaine, amphetamines, and ephedrine.
V Leiden mutations, prothrombin G20210A gene Ischemia can also affect blood vessel walls, leading to
mutations, homocysteine levels, and the C677T mutation thrombosis and secondary inflammation, which may cause
of the methylenetetrahydrofolate reductase gene.3,4 confusion with vasculitis.
When faced with a case of livedo reticularis with purpura,
necrosis, or subcutaneous nodules, a skin biopsy should be
taken from the erythematous-violaceous or purpuric areas, Inflammation of the Blood Vessels
the margin of a necrotic lesion, or a nodule; the biopsy
should include the full thickness of the skin (reaching the Vasculitis
hypodermis). A tissue sample obtained by punch biopsy Vasculitides that affect the arterioles of the skin include
may be sufficient if the biopsy site is chosen correctly. systemic and cutaneous polyarteritis nodosa, Wegener
Punch biopsies are the method of choice for avoiding granulomatosis, Churg–Strauss syndrome, microscopic
difficult-to-heal ulcers. Pathologic analysis will reveal polyangiitis, polyangiitis associated with systemic diseases
whether or not the lesion is of inflammatory origin (Figure such as systemic lupus erythematosus and rheumatoid
2). If there is inflammation, it is important to determine arthritis, and certain types of vasculitis induced by drugs
the size of the affected vessels and to identify the types of such as thiouracil.
cells of the inflammatory infiltrate (polymorphonuclear The skin manifestations in these cases include livedo
neutrophils, mononuclear cells, or giant cells). If there is reticularis, inflammatory subcutaneous nodules, palpable
no inflammation, the biopsy findings will help to identify purpura, necrosis, and secondary ulceration (Figure 3).
the cause of vessel obstruction (eg, clot, cholesterol crystals, General signs and symptoms may be severe and vary
calcium, endothelial proliferation, hyalinization). On the according to the underlying disease and the organs affected,
basis of these data, further investigations will be indicated meaning that systemic examination will reveal key diagnostic
to determine possible causes and initiate appropriate clues. Skin biopsy will help determine the type of blood
treatment; in patients with severe symptoms, urgent vessels affected and the nature of the inflammatory
treatment may be required. infiltrate.5 Polyarteritis nodosa almost exclusively affects
the deep plexus while the other conditions can affect both
the deep and superficial plexuses. The involvement of the
Arteriolar Spasm small superficial, caliber vessels explains the clinical presence
of palpable purpura in Wegener granulomatosis,
Arteriolar smooth muscle can respond to different stimuli, Churg–Strauss syndrome, and polyangiitis. Inflammatory
triggering vasoconstriction; this may be physiological, such infiltrates in the superficial plexus are formed of
B
Livedo reticularis + nodules + necrosis
Eosinophilic material
Biconcave spaces
Type I cryoglobulinemia
Figure 2. A and B, diagnostic Calcium
Birefringent crystals
algorithms based on the Cholesterol
pathologic study of livedo
reticularis in association with
Calciphylaxis
nodules or necrosis. SLE Hyperoxaluria
indicates systematic lupus
erythematosus.
Thrombosis
inappropriate treatment carries a high risk of serious 3. Callen JP. Livedoid Vasculopathy: What it is and how the
consequences.5,30 patient should be evaluated and treated. Arch Dermatol.
Systemic vasculitis should be treated with corticosteroids 2006;142:1481-2.
4. Hairston BR, Davis M, Pittelkow MR, Ahmed I. Livedoid
and immunosuppressants; doses and combinations will vary Vasculopathy: Further evidence for procoagulant pathogenesis.
according to the clinical condition of the patient and the Arch Dermatol. 2006;142:1413-8.
extent of organ involvement. Serious organ dysfunction requires 5. Carlson JA, Chen KR. Cutaneous vasculitis update:
the use of corticosteroids and cyclophosphamide pulse therapy. Neutrophilic muscular vessel and eosinophilic, granulomatous,
Combining low doses of corticosteroids with methotrexate and lymphocytic vasculitis syndromes. Am J Dermatopathol.
or azathioprine is a good option for maintenance treatment, 2007;29:32-43.
and cotrimoxazole is recommended for maintenance in 6. Bosch X, Guilabert A, Font J. Antineutrophil cytoplasmic
antibodies. The Lancet. 2006;368:404-18.
Wegener granulomatosis to treat lung dysfunction. 7. Carlson JA, Chen KR. Cutaneous Pseudovasculitis. Am J
There is no effective treatment for generalized livedo Dermatopathol. 2007;29:44-55.
reticularis in antiphospholipid syndrome or Sneddon 8. Grau R. Pseudovasculitis: mechanisms of vascular injury and
syndrome. Skin lesions due to thrombosis can be treated clinical spectrum. Curr Rheumatol Rep. 2002;4:83-9.
with low doses of aspirin or antiplatelet therapy, although 9. Blume JE, Miller CC. Antiphospholipid syndrome: a review
some cases may require coumarin anticoagulants.31 and update for the dermatologist. Cutis. 2006;78:409-15.
10.Grob JJ, Bonerandi JJ. Cutaneous manifestations associated
Patients with livedoid vasculitis or disorders secondary to
with the presence of the lupus anticoagulant. A report of two
thrombophilia are advised first of all to quit smoking or to cases and a review of the literature. J Am Acad Dermatol.
use nicotine patches or gum. Appropriate drug treatment 1986;15:211-9.
involves the use of aspirin, pentoxifylline, dipyridamole, and 11.Oh YB, Jun JB, Kim CK, Lee CW, Park CK, Kim TY, et al.
hyperbaric oxygen. Some authors have indicated that better Mixed connective tissue disease associated with skin defects
results will be achieved when these drugs are combined with of livedoid vasculitis. Clin Rheumatol. 2000;19:381-4.
immunosuppressants32 or intravenous immunoglobulin.33 12.Acland KM, Darvay A, Wakelin SH, Russell-Jones R. Livedoid
vasculitis: a manifestation of the antiphospholipid syndrome?
Hydroxychloroquine is the treatment for livedo reticularis
Br J Dermatol. 1999;140:131-5.
in patients with antiphospholipid syndrome.3,34 Danazol 13.Calamia KT, Balabanova M, Perniciario C, Walsh JS. Livedo
or stanozolol can be prescribed to patients with (livedoid) vasculitis and the factor V Leiden mutation: additional
cryofibrinogenemia, and coumarins or low molecular weight evidence for abnormal coagulation. J Am Acad Dermatol.
heparin may be indicated for certain hypercoagulable states. 2002;46:133-7.
Patients with methylenetetrahydrofolate reductase mutation 14.Boyvat A, Kundakci N, Babikir MO, Gurgey E. Livedoid
can be treated with folic acid while those with plasminogen- vasculopathy associated with heterozygous protein C deficiency.
Br J Dermatol. 2000;143:840-2.
1 activator inhibitor abnormalities can be administered an 15.Tran MD, Becherel PA, Cordel N, Piette JC, Frances C.
intravenous infusion of tissue plasminogen activator. «Idiopathic» white atrophy. Ann Dermatol Venereol. 2001;
There are no clearly effective treatments for embolic 128:1003-7.
diseases, calciphylaxis, or hyperoxaluria, all serious conditions 16.Deng A, Gocke CD, Hess J, Heyman M, Paltiel M, Gaspari
whose most severe complication is obstruction of the renal A. Livedoid vasculopathy associated with plasminogen activator
arteries and subsequent renal failure, which requires specific inhibitor-1 promoter homozygosity (4G/4G) treated
treatment. Systemic corticosteroids should be recommended successfully with tissue plasminogen activator. Arch Dermatol.
2006;142:1466-9.
treatment for cholesterol emboli as they appear to halt the 17.Requena L, Kutzner H, Angulo J, Renedo G. Generalized
secondary inflammatory cascade that can have fatal livedo reticularis associated with monoclonal cryoglobulinemia
consequences. and multiple myeloma. J Cutan Pathol. 2007;34:198-202.
18.Morell A, Botella R, Silvestre JE, Betlloch I, Alfonso MR,
Conflicts of Interest Ruiz MD. Livedo reticularis and thrombotic purpura related
The authors declare no conflicts of interest. to the use of diphenhydramine associated with pyrithyldione.
Dermatology. 1996;193:50-1.
19.Labropoulos N, Manalo D, Patel NP, Tiongson J, Pryor L,
Giannoukas AD. Uncommon leg ulcers in the lower extremity.
References J Vasc Surg. 2007;45:568 - 573.
20.Ruzzon E, Raudi ML, Tezza F, Luzzatto G, Scandellari R,
1. Ackerman AB. Histologic diagnosis of inflammatory skin Fabris F. Leg ulcers in elderly on hydroxyurea: a single disorder
diseases. A method by pattern analysis. 1st ed. Philadelphia: in Ph-myeloproliferative disorders and review of literature.
Lea Febiger; 1978. Aging Clin Exp Res. 2006,18:187-90.
2. Frances C, Papo T, Wechsler B, Laporte JL, Biousse V, Piette 21.Sirieix ME, Debure C, Baudot N, Dubertret L, Roux ME,
JC. Sneddon syndrome with or without antiphospholipid Morel O, et al. Leg ulcers and hydroxyurea: forty-one cases.
Arch Dermatol. 1999;135:818-20.
antibodies. A comparative study in 46 patients. Medicine
22.Duffau P, Beylot-Barry M, Palussiere J, Ly S, Cogrel O. Necrotic
(Baltimore). 1999;78:209-19.
livedo after vertebroplasty. Br J Dermatol. 2007;156:382-3.
23.Yebenes M, Gilaberte M, Toll A, Barranco C, Pujol RM. 29.Somach SC, Davis BR, Paras FA, Petrelli M, Behmer ME.
Púrpura retiforme después de inyección intraarterial accidental Fatal cutaneous necrosis mimicking calciphylaxis in a patient
de polidocanol. Acta Derm Venéreol. 2005;85:372-3. with type 1 primary hyperoxaluria. Arch Dermatol. 1995;
24.Jucgla A, Moreso F, Muniesa C, Moreno A, Vidaller A. 131:821-3.
Cholesterol embolism: still an unrecognized entity with a high 30.Ribi C, Mauget D, Egger JF, Khatchatourian G, Villard J.
mortality rate. J Am Acad Dermatol. 2006;55:786-93. Pseudovasculitis and corticosteroid therapy. Clin Rheumatol.
25.Nahm WK, Badiavas E, Touma DJ, Wilkel CS, Falanga V. 2005;24:539-43.
Calciphylaxis with peau d’orange induration and absence of 31.García-García C. Anticuerpos antifosfolípido y síndrome
classical features of purpura, livedo reticularis and ulcers. J antifosfolípido: actitudes diagnósticas y terapéuticas. Actas
Dermatol. 2002;29:209-13. Dermosifiliogr. 2007;98:16-23.
26.Kyttaris VC, Timbil S, Kalliabakos D, Vaiopoulos G, Weinstein 32.Lee SS, Ang P, Tan SH. Clinical profile and treatment out-
A. Calciphylaxis: a pseudo-vasculitis syndrome. Semin Arthritis come of livedoid vasculitis: a case series. Ann Acad Med
Rheum. 2007;36:264-7. Singapore. 2003;32:835-9.
27.Bogle MA, Teller CF, Tschen JA, Smith CA, Wang A. Primary 33.Schanz S, Ulmer A, Fierlbeck G. Intravenous immunoglobulin
hyperoxaluria in a 27-year-old woman. J Am Acad Dermatol. in livedo vasculitis: a new treatment option? J Am Acad
2003;49:725-8. Dermatol. 2003;49:555-6.
28.Manganoni AM, Venturini M, Scolari F, Tucci G, Facchetti 34.Amato L, Chiarini C, Berti S, Massi D, Fabbri P. Idiopathic
F, Graifemberhi S, et al. The importance of skin biopsy in the atrophie blanche. Skinmed. 2006;5:151-4.
diverse clinical manifestations of cholesterol embolism. Br J 35.Sepp N. Other vascular disorders. In: Bolognia JL, Jorizzo J,
Dermatol. 2004;150:1230-1. Rapini RP. Dermatology. London: Mosby; 2003. p. 1651-9.